At the European Society of Medical Oncology annual congress (September 26-30, 2019; Barcelona, Spain), a variety of important studies were highlighted on PARP inhibitors across a variety of disease types.
Journal of Clinical Pathways was onsite to provide coverage of the most relevant and important sessions of the meeting.
PARP Inhibitors in Front-Line and Maintenance Therapy of Ovarian Cancer: A Changing Standard of Care
Robert L Coleman, MD, The University of Texas MD Anderson Cancer Center, discusses the potential integration of veliparib with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, as well as the larger PARP inhibitor landscape in this setting.
New data demonstrates the benefit of a more intensive maintenance combination regimen for ovarian cancer regardless of BRCA mutation.
A clinically meaningful benefit in radiographic PFS after PARP inhibitor therapy was observed in men with metastatic, castration-resistant prostate cancer who had progressed on prior therapy.
The combination of a PARP inhibitor with front-line combination chemotherapy and continued PARP inhibitor maintenance significantly extends PFS in patients with newly diagnosed ovarian serous carcinoma, according to new research.